B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers [Phase 1]
Phase 1 study of oral LOXO-338 in advanced blood cancers is ongoing, with status listed as active but not recruiting.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating the safety and early efficacy of BAFF-R CAR-T cells in adults with CD19-negative relapsed or refractory B-…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma [Phase 1]
Phase 1 trial update reporting completion of a study evaluating CD19-targeted CAR T cells in relapsed or refractory CD19-positive B-cell lym…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating an in vivo CD19-targeted CAR-T/M therapy delivered by an oncolytic vaccinia virus for refractory/relapse…
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating the safety and efficacy of combining favezelimab (MK-4280) with pembrolizumab (MK-3475) in patients wi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma [EARLY_Phase 1]
Phase I master protocol trial evaluating a novel combination therapy for patients with relapsed or refractory aggressive B-cell lymphomas.
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Venetoclax Plus Inotuzumab for B-ALL [Phase 1]
This is an update on a Phase 1 trial of venetoclax plus inotuzumab ozogamicin for B-cell acute lymphoblastic leukemia and B-cell lymphoma; t…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial of the oral BTK inhibitor LOXO-305 (pirtobrutinib) in patients with previously treated chronic lymphocy…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study evaluating universal CD19 CAR-γδT cell injections for adults with relapsed or refractor…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Anti CD19 Gene Therapy for B-cell Lymphoma [NA]
A clinical trial is recruiting for an anti CD19 gene therapy to treat B-cell lymphoma.
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors [EARLY_Phase 1]
A Phase 1 trial evaluating universal CAR-T cells (REVO-UWD-19) for refractory or relapsed B-cell malignancies is currently recruiting, spons…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia [Phase 2]
Phase 2 clinical trial evaluating polymer-lipid particle-delivered CAR1920 mRNA CAR-T therapy for relapsed/refractory B-cell lymphoma and le…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma [NA]
This clinical trial update describes a study evaluating clearance of minimal residual disease at the end of first-line treatment in patients…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) [Phase 1]
This Clinical Trial Update describes BaseCAR-01, a Phase 1 study evaluating bispecific CAR T cells in B-cell malignancies, with recruitment …
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: CD22 Redirected Autologous T Cells for ALL [Phase 1]
Phase 1 clinical trial update on autologous T cells redirected to CD22 for B-cell leukemias and lymphomas, sponsored by the University of Pe…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) [NA]
Clinical trial update on adaptive bridging radiotherapy for relapsed/refractory B-cell lymphomas prior to CAR-T therapy; the study status is…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma [Phase 1]
Phase 1 clinical trial update of anti-CD19 CAR-T cells with an inducible caspase-9 safety switch for B-cell lymphoma, currently active but n…
-
CLINICAL_TRIALS other · 2025-12-08Clinical Trial Update: Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma [Phase 4]
A Phase 4 clinical trial is evaluating zanubrutinib in combination with rituximab for secondary hemophagocytic lymphohistiocytosis in patien…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Clinical trial update describing a follow-up protocol for individuals previously enrolled in CAR-T cell studies, detailing a gene therapy fo…
-
EMA approval · 2025-11-25EMA Authorised: Zynlonta (loncastuximab tesirine) — Swedish Orphan Biovitrum AB
The European Medicines Agency authorized Zynlonta (loncastuximab tesirine) for diffuse large B-cell lymphoma and B-cell lymphoma, under a co…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Universal CAR-T Cell Therapy for NHL [NA]
Recruitment is ongoing for a universal CAR-T cell therapy being studied in non-Hodgkin lymphoma (B-cell subtype), sponsored by Bioray Labora…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas [Phase 1]
A Phase 1 study evaluating JV-213, an autologous CD79b-targeting CAR T-cell therapy, in adults with relapsed or refractory B-cell lymphomas;…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. [Phase 4]
This Phase 4 trial update describes extending ibrutinib treatment for patients who continue to benefit from the therapy.
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas [Phase 1]
A Phase 1 dose-finding study of ASP2802 in CD20-positive B-cell lymphomas was conducted, but the study has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) [Phase 1, Phase 2]
This clinical trial update reports safety and efficacy data for CTX110 in relapsed or refractory B-cell malignancies, including Non-Hodgkin …